Europe Cardiac Ablation Market size crossed USD 980 million in 2021 and is anticipated to expand at a CAGR of 14.3% between 2022 and 2028.

Get more details on this report - Request Free Sample PDF

Cardiac ablation is a minimally invasive procedure that uses heat or energy to form scars in heart intended to block abnormal electrical signals and further restores normal heartbeat. The procedure is also recognized as catheter ablation, wherein it uses radiofrequency energy for the destruction of a small area of heart tissue.

The Europe cardiac ablation market is majorly driven by increasing incidence of cardiovascular diseases leading to rise in the number of treatment procedures. According to the data published by the European Heart Network in 2020, the cardiovascular diseases are responsible for nearly 3.9 million deaths each year across the region. Thus, to minimize disease burden and associated mortalities, the industry players are continuously focusing on product development strategies. Technological advancement in cardiac ablation devices offers ease and increases procedural efficiency.

Growing awareness regarding the availability of advanced treatment procedures will benefit the product adoption rate. Favourable initiatives by the government as well as non-government organizations to expand treatment accessibility and educate people about the available disease treatments will strengthen the industry growth potential. For instance, the European Heart Rhythm Association aims to promote and raise awareness regarding the heart rhythm disorders, and other cardiac disorders. Furthermore, collaborative efforts by the non-profit organizations and companies to provide cost-effective treatment will positively impact procedural volume.

The industry continued to witness product demand with declining prevalence of COVID-19 in 2021. The healthcare facilities experienced increased patient inflow suffering through cardiovascular diseases due to the minimized risk of COVID-19 infection with standard safety and operational guidelines. With gradual increase in number of cardiovascular procedures, the market participants also experienced momentous product demand.

Europe Cardiac Ablation Market, By Product

The radiofrequency ablators segment exceeded USD 580 million revenue in 2021, attributed to procedural benefits such as cost-effectiveness, expanded availability, increased awareness, and quick relief. Furthermore, increasing prevalence of atrial fibrillation driving the preference for minimally invasive surgical procedures in the Europe will augment the market growth. For instance, as per the European Society of Cardiology, nearly 14.4 million individuals are projected to have atrial fibrillation by 2060 in the Europe.

Europe Market, By Approach

The catheter-based segment dominated more than 72% Europe cardiac ablation market share in 2021. Growing prevalence of tachyarrhythmia and cardiac arrhythmias along with other conditions leading to irregular heart rhythm is one of the leading factors contributing to the growth of catheter-based ablation. Additionally, collaborative efforts by the healthcare facilities and market players to develop advanced and highly efficient ablation catheters aimed to offer reduced procedure time, enhanced safety, cost-effectiveness and improved outcomes will favor the segment growth.

Europe Market, By Application

 Atrial fibrillation & flutter segment will witness around 15.7% growth rate during the forecast timeframe. The increasing prevalence of risk factors such as alcohol and substance misuse, smoking, ingestion of certain drugs and consumption of high amounts of caffeine is contributing to the increased risk of atrial flutter.

Europe Market, By End-use

Get more details on this report - Request Free Sample PDF

The hospitals end-use segment held over 60% Europe cardiac ablation market share in 2021, owing to the increasing rate of patient admissions. Expanded network of hospitals across developing as well as developed European countries increases the treatment accessibility to patients in these settings, Thus, the companies are focusing on broadening product availability in hospitals to cater huge patient population.

Europe Market, By Country

Germany cardiac ablation market accounted over 20% revenue share in 2021, credited to rising geriatric population base. Elderly population is more prone to cardiovascular diseases as aging leads to structural changes in heart and vessels, thus contributing to the national disease burden. The number of people aged 65 years and older in Germany is anticipated to reach nearly 24 million by 2050. Thus, the higher risk of cardiac arrhythmias and other heart diseases among geriatric population will benefit the number of ablation procedures in the country. Additionally, availability of sophisticated healthcare infrastructure and presence of leading players offering advanced devices will positively impact procedural rate.

Competitive Industry Landscape

Some of the notable players involved in the Europe cardiac ablation market include Abbott Laboratories (St. Jude Medical), AngioDynamics, Inc, Biosense Webster (Johnson & Johnson), Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic plc, MicroPort Scientific Corporation, Stereotaxis, Inc, Smith & Nephew PLC, and Olympus Corporation.

The industry players are undertaking several strategic initiatives such as product launches, acquisition & merger and collaborations to expand their market footprint. For instance, in June 2021, Acutus Medical announced the launch of AcQBlate Force Sensing Ablation System in the Europe.